ProQR Therapeutics stock inched up 3.8% to €1.92 after its Q2 release, a calm move for a biotech that often trades on emotion first and fundamentals second. The headline this quarter is the sharp step up in revenue to €8.759 million while losses narrowed to a net loss of €8.728 million. That mix of stronger top line and still heavy red ink is what the market is trying to price. The question now is whether a modest bounce fully reflects that shift in the income statement or if investors are only cautiously warming to the story.

Is ProQR Therapeutics now priced for years of 51% revenue growth, or are investors overpaying for a stock that is still loss making with forecast earnings declines and recent dilution on the table? See how its current multiples compare and whether the premium P/S looks stretched or justified in the full valuation analysis for ProQR Therapeutics

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: €8.759 million vs. €3.975 million (very large increase)
• Net Loss Q2 2026 vs. Q2 2025: €8.728 million loss vs. €12.179 million loss (loss narrowed by about 28%)
• Basic EPS Q2 2026 vs. Q2 2025: €0.079 loss per share vs. €0.116 loss per share (per share loss improved by about 32%)
• Trailing 12 Month Revenue to Q2 2026 vs. TTM to Q2 2025: €18.423 million vs. €17.14 million (up about 7%)

Prefer clean charts instead of another wall of Q2 figures and income statement footnotes? See ProQR Therapeutics' full visual breakdown with a focus on its valuation in the company report for ProQR Therapeutics.

ProQR bullish story meets improving income trend

For investors leaning into the ProQR Therapeutics platform and Eli Lilly link, the latest quarter gives some support. Revenue moved to €8.759 million in Q2 2026 from €3.975 million a year earlier, and trailing 12 month revenue is now €18.423 million. The net loss narrowed to €8.728 million from €12.179 million, and the loss per share improved. That combination of stronger top line and lower loss fits a cautiously optimistic view that the business model is gaining traction, even while it remains firmly in investment mode.

Losses and funding risk still anchor the bear view

The bearish side of the ProQR Therapeutics story is not disproved by these numbers. The company still reports a quarterly loss of €8.728 million and remains dependent on external funding or partnerships to support its RNA editing pipeline. Trailing 12 month revenue of €18.423 million is modest against typical biotech development costs. Recent share price gains of 20.75% over 90 days suggest some optimism, yet that move arrives with ongoing losses and the possibility of future dilution still front of mind for many investors.

Compare how ProQR Therapeutics' revenue progress and still sizeable losses stack up against Wall Street expectations, and whether analysts see this as the start of a real turnaround or just a brief rerating, by checking the consensus price target analysis for ProQR Therapeutics.

Take Control of Your Next Move

If ProQR Therapeutics' stronger revenue and narrower loss have caught your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on how the share price lines up against fair value for a potential entry point. Once you decide to build a position, use the Portfolio Command Center to cut through market noise and stay on top of the most important changes to your holdings. For a longer term view, tap into crowd insights and different angles on ProQR Therapeutics and other stocks through the Community. This way you can spot hidden catalysts or emerging risks early and stay a step ahead of the market.

Seeking Alternatives Beyond ProQR Therapeutics?

Fresh stock ideas can move from quiet potential to full breakout before most investors react. Use these under the radar lists while it matters and get in early.

• Spot companies building real momentum with strong balance sheets and solid cash flows by scanning a curated 50 high quality undervalued stocks before the crowd catches on and prices move.
• Track early leaders in nuclear build out and reactor infrastructure using a focused list of 91 nuclear energy infrastructure stocks while valuations still look reasonable for long term holders.
• Zero in on miners with production scale and discipline by reviewing hand picked 30 elite gold producer stocks before any renewed interest drives increased attention to quality gold producers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.